主页 > 医药科学 >
【medical-news】英夫利昔单抗对巨细胞动脉炎或风
NEW YORK (Reuters Health) Apr 30 - Infliximab is not an effective treatment for giant cell arteritis or polymyalgia rheumatica and may actually be harmful, according to the results of two placebo-controlled trials appearing in the Annals of Internal Medicine for May 1.
In the first study, Dr. Gary S. Hoffman, from the Cleveland Clinic Foundation, and colleagues assessed the benefits of infliximab in 44 patients with newly diagnosed giant cell arteritis that was in steroid-induced remission.
Twenty-eight patients were randomized to infliximab 5 mg/kg of body weight plus glucocorticosteroids and 16 to placebo plus glucocorticosteroids.
At week 22, the proportion of patients in the infliximab group who relapsed was actually higher than that in the placebo group: 57% vs. 50% (p = 0.65). Moreover, infliximab use did not increase the proportion of patients who were able to taper their steroid dosages without relapse.
Infliximab use seemed to increase the risk of infection, the report indicates. Seventy-one percent of patients treated with the drug developed an infection compared with 56% of control subjects.
The second study, conducted by Dr. Carlo Salvarani, from Arcispedale S. Maria Nuova in Reggio Emilia, Italy, and colleagues, yielded similar results -- this time in patients with polymyalgia rheumatica. The study included 51 patients with newly diagnosed disease who were randomized to receive prednisone in combination with infliximab or placebo.
The disease relapse-free rate at 52 weeks was not significantly different between the groups -- 30% in the infliximab group vs. 37% in controls.
Eight adverse events were recorded in each group with no significant differences observed, the report indicates.
While the findings suggest that in the very least, infliximab is not effective for these diseases, the authors of both studies caution that because of the small sample sizes, the results should not be considered definitive.
In light of these null findings, editorialist Dr. Raashid Luqmani, from the University of Oxford in the UK, comments that for now "giant cell arteritis and polymyalgia rheumatica remain therapeutic challenges. For physicians who manage these diseases, the message is that steroids are still the cornerstone of treatment."
Ann Intern Med 2007;146:621-639,674-675.
http://www.medscape.com/viewarticle/555877 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Infliximab Ineffective for Giant Cell Arteritis or Polymyalgia Rheumatica
英夫利昔单抗对巨细胞动脉炎或风湿性多肌痛无效
NEW YORK (Reuters Health) Apr 30 - Infliximab is not an effective treatment for giant cell arteritis or polymyalgia rheumatica and may actually be harmful, according to the results of two placebo-controlled trials appearing in the Annals of Internal Medicine for May 1.
纽约（路透社 健康专栏）4.30－据5月1日《内科学》年报上的两项安慰剂-对照试验结果显示，英夫利昔单抗对治疗巨细胞动脉炎或风湿性多肌痛无效，而且可能会有害。
In the first study, Dr. Gary S. Hoffman, from the Cleveland Clinic Foundation, and colleagues assessed the benefits of infliximab in 44 patients with newly diagnosed giant cell arteritis that was in steroid-induced remission.
在第一项研究中，克立夫兰临床基金的Gary S. Hoffman博士及其同事评价了英夫利昔单抗对44名新近诊断出巨细胞动脉炎患者的治疗效果，这些患者通过类固醇药物可以减轻症状。
Twenty-eight patients were randomized to infliximab 5 mg/kg of body weight plus glucocorticosteroids and 16 to placebo plus glucocorticosteroids.
28名患者被随机分入英夫利昔单抗5 mg/kg体重联合糖皮质类固醇组，16名分入安慰剂联合糖皮质类固醇组。
At week 22, the proportion of patients in the infliximab group who relapsed was actually higher than that in the placebo group: 57% vs. 50% (p = 0.65). Moreover, infliximab use did not increase the proportion of patients who were able to taper their steroid dosages without relapse.
在第22周，英夫利昔单抗组患者的复发比率明显高于安慰剂组，57% ：50% (p = 0.65)。另外，使用英夫利昔单抗不会增加减少类固醇用量而不复发的患者比率。
Infliximab use seemed to increase the risk of infection, the report indicates. Seventy-one percent of patients treated with the drug developed an infection compared with 56% of control subjects.
报告指出，使用英夫利昔单抗似乎会增加感染风险。使用该药治疗的患者有71％出现感染，而对照组为56%。
The second study, conducted by Dr. Carlo Salvarani, from Arcispedale S. Maria Nuova in Reggio Emilia, Italy, and colleagues, yielded similar results -- this time in patients with polymyalgia rheumatica. The study included 51 patients with newly diagnosed disease who were randomized to receive prednisone in combination with infliximab or placebo.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-21 17:11
医学,生命科学网